Curated News
By: NewsRamp Editorial Staff
January 31, 2025
United Health Products Updates FDA Application and Capital Markets Activities
Discuss on Reddit
LinkedIn
Substack
Telegram
GithubTLDR
- UHP expects to submit additional responses to FDA in early February, advancing its study protocol and potentially gaining a competitive edge.
- UHP submitted an IDE to FDA in November, resolving concerns on testing protocols and aiming to complete the clinical study report by mid-summer.
- UHP's CelluSTAT aims to control bleeding, seeking FDA approval to access the surgical market, potentially improving patient outcomes.
- UHP raised over $400,000 for clinical study, applied for OTCQB uplisting, and developed training materials for investigator, showing proactive progress.
Impact - Why it Matters
This news highlights the progress of United Health Products towards conducting a clinical study for its hemostatic agent. The successful approval of its FDA application and funding efforts can potentially lead to the commercialization of CelluSTAT, offering a natural solution for controlling bleeding. Investors and healthcare professionals should closely monitor UHP's developments as it moves closer to accessing the human surgical market.
Summary
United Health Products, Inc. provided an update on its regulatory and capital markets activities, including progress with the FDA's IDE application and preparations for a clinical study. The company has identified suitable surgical sites for the study and is working on securing funds through private placements. UHP is also seeking an uplisting of its shares to the OTCQB exchange to attract more investors.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, United Health Products Updates FDA Application and Capital Markets Activities
